Biogen Idec options neurodegenerative technology from Amorfix
Amorfix Life Sciences (diagnostics and treatments for neurodegenerative diseases) granted Biogen Idec an option to license exclusive worldwide rights to a technology that BI can use to develop and sell treatments for amyotrophic lateral sclerosis (ALS).
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com